Medical Devicesworld trade 2024+5.1% 5Y CAGR
Mar 23, 2023NEW FACILITYOsaka, Juso, Japan Takeda to build 100 billion yen plasma-derived therapy plant in Osaka, Japan
Takeda announced a long-term investment of approximately 100 billion yen to build a new plasma-derived therapy manufacturing facility at its Osaka plant in Juso, Japan. The facility will have a plasma processing capacity of over 2 million liters per year and is expected to start operations around 2030.
Value
$750.0M (100.0B JPY)
Capacity
2 million liters per year
Productsplasma-derived therapies
“当社は、日本の大阪・十三に血漿分画製剤の新製造施設を建設するため、1,000億円規模の長期投資を行うことを決定しましたので、お知らせします。”takeda.com
- 2 sources
- takeda.com日本における血漿分画製剤の新製造施設建設に向けた1,000億円規模の投資計画を通じた 患者さんへのさらなる貢献についてTakeda Pharmaceutical Company LimitedMar 23, 2023
- takeda.comTakeda to Invest 100 Billion JPY in a New Manufacturing Facility for Plasma-Derived Therapies in JapanTakeda Pharmaceutical Company LimitedMar 23, 2023
Summarized from public sources; check the original articles before acting on it.
ENDATA